Ispecimen Inc. SEC Filings

Welcome to our dedicated page for Ispecimen SEC filings (Ticker: ISPC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

The iSpecimen Inc. (ISPC) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. iSpecimen’s filings offer detailed information about its online marketplace for human biospecimens, its capital structure, financing activities, governance, and interactions with The Nasdaq Capital Market. Stock Titan enhances these documents with AI-powered summaries designed to explain the key points of each filing in clear language.

For investors and analysts reviewing annual reports on Form 10-K and quarterly reports on Form 10-Q, iSpecimen’s disclosures describe its mission to accelerate life science research through a global biospecimen marketplace, its technology platform, and its classification as an emerging growth company and smaller reporting company. These periodic reports, when available, are central sources for understanding the company’s business model, risk factors, and operating environment.

Current reports on Form 8-K provide timely updates on material events. Recent 8-K filings include a November 21, 2025 report describing a Nasdaq notice that the company’s closing bid price had fallen below the $1.00 minimum required under Listing Rule 5550(a)(2), along with the timeframe provided to regain compliance. Other 8-Ks detail leadership changes, such as the appointment of a new Chief Executive Officer and the addition of an independent director, and report the results of a special meeting of stockholders where proposals related to a reverse stock split, an increase in authorized shares, private financing approvals, amendments to convertible securities, and an equity line of credit were approved.

Proxy statements on Schedule 14A (DEF 14A) shed light on corporate governance, director elections, stock incentive plans, and the agenda for annual and special meetings. The 2025 special meeting proxy statement outlines proposals to adjust the company’s capital structure and financing flexibility, while the 2025 annual meeting proxy statement covers director elections, auditor ratification, and a new stock incentive plan.

iSpecimen’s registration statements on Form S-1 and S-1/A describe offerings of common stock and pre-funded warrants, the use of proceeds, and detailed background on the company’s marketplace model. These filings also incorporate discussion of the company’s corporate treasury plan related to the Solana blockchain ecosystem and associated risk factors, as noted in the explanatory notes to recent amendments.

On Stock Titan, users can review these ISPC filings as they are updated in real time from EDGAR, while AI-generated overviews highlight important elements such as capital-raising terms, listing compliance matters, governance proposals, and structural changes to outstanding securities. This combination of source documents and AI explanations helps readers navigate complex forms, from 10-Ks and 10-Qs to 8-Ks, S-1 registration statements, and proxy materials, and track how iSpecimen manages its biospecimen marketplace business within the public-company regulatory framework.